Design, synthesis and biological evaluation of new series of hexahydroquinoline and fused quinoline derivatives as potent inhibitors of wild-type EGFR and mutant EGFR (L858R and T790M)
作者:Mennatallah A. Shaheen、Ali A. El-Emam、Nadia S. El-Gohary
DOI:10.1016/j.bioorg.2020.104274
日期:2020.12
New series of hexahydroquinoline and fused quinoline derivatives were designed and synthesized. The thirty seven new compounds were screened for in vitro antitumor activity against HepG2, HCT-116 and MCF-7 cancer cells. Results indicated that compounds 2e, 2h, 5b, 5c, 6a, 7d and 9b have the strongest potency against the three cancer cells, and they were further screened for in vitro cytotoxicity against
设计并合成了一系列新的六氢喹啉和稠合喹啉衍生物。筛选了三十七个新化合物对HepG2,HCT-116和MCF-7癌细胞的体外抗肿瘤活性。结果表明化合物2e,2h,5b,5c,6a,7d和9b对这三种癌细胞具有最强的效力,并且进一步筛选了它们对A431和H1975癌细胞以及WI38和WISH正常细胞的体外细胞毒性细胞。结果显示,与 过表达EGFR WT(IC )的A431细胞相比,7d有效抑制了带有EGFR T790M突变(IC 50 = 1.32±0.2 µM)的H1975细胞的生长50 = 4.96±0.3 µM)。此外,这七个化合物对测试的正常细胞显示出低细胞毒性。检查了七种有效的抗肿瘤化合物抑制EGFR WT活性的能力。获得的数据表明, 与厄洛替尼(IC 50 = 0.067± 0.002μM)相比,7d具有显着的EGFR WT抑制活性(IC 50 = 0.083± 0.002μM